MiNK Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 10.875 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 55.50M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients wit...